Introduction {#S0001}
============

Esophageal cancer (EC) represents the sixth most frequent cause of cancer-related deaths worldwide.[@CIT0001],[@CIT0002] Over half of all EC-related deaths occur in China where esophageal squamous cell carcinoma (ESCC) is the predominant histologic subtype, particularly in high-risk populations.[@CIT0003],[@CIT0004] Despite the rapid development of medical techniques and the continuous improvement of techniques for early diagnosis of EC, advanced cases still account for approximately 50% of the clinical diagnoses, and the overall five-year survival rate with EC is 15--25%.[@CIT0005] Therefore, early detection of tumors provides effective treatments and timely interventions, which may improve the outcomes. Determination of molecular markers of early-stage cancer is urgently required to improve patient prognosis.

Long non-coding RNAs (lncRNAs) are novel families of long (\>200 nucleotides), lacking protein-coding ability, which has been discovered to have a critical role in regulating gene expression and oncogenic pathways.[@CIT0006]--[@CIT0008] Several lncRNAs were recently found to play important roles in modulating ESCC development.[@CIT0009],[@CIT0010] Among many of the cancer-associated lncRNAs, the serine peptidase inhibitor, Kunitz type 1 antisense RNA1 (*SPINT1-AS1*), a member of the Kunitz family of serine protease inhibitors, inhibits multiple proteases activity including hepatocyte growth factor (HGF) activator and matriptase.[@CIT0011] Abnormal expression of these serine protease inhibitors has been demonstrated in several types of cancer.[@CIT0012]--[@CIT0016] However, the role of *SPINT1-AS1* in ESCC remains unintelligible.

In this study, we investigated the expression of *SPINT1-AS1* in matched ESCC and normal tissues by quantitative real-time polymerase chain reaction (qRT-PCR) method. We further analyzed the relationship between SPINT1-AS1, its corresponding sense transcript serine peptidase inhibitor, Kunitz type 1 (*SPINT1*) mRNA, and clinicopathological characteristics in ESCC. Our study provides novel insights into the role of *SPINT1-AS1* in ESCC progression, and identifies a potential new target for diagnosis and treatment of ESCC.

Materials and methods {#S0002}
=====================

Ethics statement {#S0002-S2001}
----------------

The study protocol was approved by the ethical review committee of the Third Affiliated Hospital of Xinxiang Medical University and Anyang Tumor Hospital. All the assays were conducted according to Declaration of Helsinki principles. Written informed consent was obtained from all the participants.

Recruitment of patients and controls {#S0002-S2002}
------------------------------------

A total of 99 cases of matched ESCC and normal tissues samples (3--7 cm away from the tumor margin) were obtained from Anyang Tumor Hospital (Henan, China) ranging from January 2011 to February 2012. All tissues were snap-frozen in liquid nitrogen immediately after surgical resection and then preserved at −80°C until used for total RNA extraction. All the cases were histopathologically confirmed, and there was no prior treatment to those patients. Patient demographic, clinical, and pathological data were recorded. All the tumors were confirmed to contain more than 80% tumor cells by histological examination of sequential sections. TNM staging was classified according to the American Joint Committee on Cancer (7th edition). All the personal information was concealed to ensure the privacy. The clinicopathological characteristics of the ESCC patients are summarized in [Table 1](#T0001){ref-type="table"}.Table 1Clinicopathological characteristics of 99 ESCC casesVariablesN% of casesAge (years) ≤655757.6 \>654242.4Gender Female4646.5 Male5353.5Family history Positive3636.4 Negative6363.6Drinking history (years) ≤106868.7 \>103131.3Smoking history (years) ≤106565.7 \>103434.3Differentiation Well1313.1 Moderate5454.6 Poor3232.3T classification T1--T22626.3 T37373.7N classification N05252.5 N1+ N2+ N34747.5Tumor size (cm) ≤46060.6 \>43939.4Location Upper1717.2 Middle6767.7 Low1515.1[^2]

All patients enrolled in this study have been followed up at intervals of 1--3 months through outpatient visits or telephone calls. The follow-up data were completed on July 30, 2017. The overall survival (OS) time was defined as the period from diagnosis to death or the last follow-up date.

RNA extraction, reverse transcription, and qRT-PCR {#S0002-S2003}
--------------------------------------------------

The relative expression levels of SPINT1-AS1 and SPINT1 mRNA in ESCC tissues and matched normal tissues were determined using qRT-PCR assays. Total RNA from each specimen was extracted using TRIzol reagent (Invitrogen, Thermo Fisher Scientific, Inc., Carlsbad, California, USA). RNA concentration was determined by ScanDrop Nuclear Acid Analyzer (Analytikjena, German). The PrimeScript RT Reagent Kit (Invitrogen, Thermo Fisher Scientific, Inc., Carlsbad, California, USA) was used for reverse transcription. The levels of mRNA of *SPINT1* expression and glyceraldehyde 3-phos-phate dehydrogenase (*GAPDH*) were determined using the ABI 7500 FAST sequence detection system (Applied Biosystems, Thermo Fisher Scientific, Inc., Carlsbad, California, USA). Triplicates of each target genes and each specimen were used, with GAPDH as an internal standard. The manufacturer's instructions for each kit were followed during the whole process. The primer sequences used are listed in [Table 2](#T0002){ref-type="table"}. The relative expression levels of target genes were calculated by using the 2^−ΔΔCt^ method.Table 2Primer sequences for reverse transcription quantitative polymerase chain reactionGenePrimer sequence (5′--3′)*SPINT1-AS1*ForwardGCCCTGGAGGATGAGAGReverseCAGATGCTGTTGGCTAAAGA*SPINT1 mRNA*ForwardACCTGTCAGCCCACCCAGTTReverseCCACGCAGTGCCCTTTGTCA*GAPDH*ForwardGTGGAGTCCACTGGCGTCTTReverseGTGCAGGAGGCATTGCTGAT

Statistical analysis {#S0002-S2004}
--------------------

All of the data were analyzed using SPSS 22.0 statistical software (SPSS Inc., Chicago, IL, USA) and GraphPad Prism software (GraphPad Software, San Diego, CA, USA). Chi-squared test was used to evaluate the relationship between *SPINT1-AS1* and *SPINT1 mRNA* and clinicopathological characteristics, and independent two-tailed *t*-test was used to analyze the statistical differences in *SPINT1-AS1* and *SPINT1 mRNA* expression in ESCC tissues and matched normal tissues. Receiver operating characteristic (ROC) curve was performed, and the area under the ROC curve (AUC) was calculated to evaluate the diagnostic value of *SPINT1-AS1* and *SPINT1 mRNA* in ESCC. Survival analysis was conducted by Kaplan--Meier method and log-rank test. Spearman's correlation analysis was used to investigate the correlation between the expression of *SPINT1-AS1* and *SPINT1 mRNA*. The hazard ratio (HR) and the 95% confidence interval (95% CI) were calculated by using Cox proportional hazards regression. Univariate and multivariate Cox regression analyses were used to assess the prognostic value of biomarkers alone and when adjusted for clinical parameters. The difference was statistically significant when *P*\<0.05.

Results {#S0003}
=======

Expression of SPINT1-AS1 in ESCC and matched normal tissues {#S0003-S2001}
-----------------------------------------------------------

qRT-PCR was done to estimate the transcriptional level of SPINT1-AS1 in 99 ESCC and matched normal tissues. Results showed that SPINT1-AS1 expression level (△Ct) in ESCC tissues and matched normal tissues is 4.786±0.258 and 3.651±0.209, respectively. In this study, we found that *SPINT1-AS1* was downregulated in ESCC tissues (*P*=0.0005, [Figure 1A](#F0001){ref-type="fig"}) and was downregulated more than twofold in 60 of the 99 ESCC tissues ([Figure 1B](#F0001){ref-type="fig"}).Figure 1*SPINT1-AS1* and *SPINT1 mRNA* expression in ESCC tissues and matched normal tissues. (**A**) qRT-PCR analysis of *SPINT1-AS1* expression level in 99 ESCC tissues and matched normal tissues (*P*=0.0005\*\*\*). Data are shown as median with interquartile range. The expression of *SPINT1-AS1* in the tissues was calculated using the △Ct method. (**B**) Expression of *SPINT1-AS1* in 99 ESCC tissues. The data are shown as fold change in ESCC tissues normalized to matched normal tissues expression (log~2~2^−△△Ct^). (**C**) qRT-PCR analysis of *SPINT1 mRNA* expression level in 99 ESCC tissues and matched normal tissues (*P*=0.0002\*\*\*). Data are shown as median with interquartile range. The expression of *SPINT1 mRNA* in the tissues was calculated using the △Ct method. (**D**) The correlation between *SPINT1-AS1* and *SPINT1 mRNA* expression levels was analyzed by Spearman's correlation analysis (*r*=0.7063, *P*\<0.0001).**Abbreviations:** ESCC, esophageal squamous cell carcinoma; *SPINT1-AS1*, serine peptidase inhibitor, Kunitz type 1 antisense RNA1; *SPINT1*, serine peptidase inhibitor, Kunitz type 1.

Relationship between SPINT1-AS1 and SPINT1 mRNA {#S0003-S2002}
-----------------------------------------------

To study the relationship between *SPINT1-AS1* and *SPINT1 mRNA*, we assessed the expression of *SPINT1 mRNA* in 99 pairs of ESCC tissues and matched normal tissues. As shown in [Figure 1C](#F0001){ref-type="fig"}, the expression level of *SPINT1 mRNA* (△Ct) was significantly downregulated in ESCC tissues (2.279±0.240) compared with matched normal tissues (1.132±0.188) (*P*=0.0002). By performing the correlation analysis, the Spearman's correlation coefficients showed a statistically positive correlation between *SPINT1-AS1* and *SPINT1 mRNA* expression in ESCC tissues (*r*=0.7063, *P*\<0.0001, [Figure 1D](#F0001){ref-type="fig"}).

Relationship between SPINT1-AS1, SPINT1 mRNA, and clinicopathological characteristics in ESCC {#S0003-S2003}
---------------------------------------------------------------------------------------------

To further explore the role of *SPINT1-AS1* and *SPINT1 mRNA* in ESCC, the correlations between *SPINT1-AS1*, *SPINT1 mRNA*, expression and the clinicopathological variables of patients with ESCC were assessed as shown in [Table 3](#T0003){ref-type="table"}. Compared with the matched normal tissues, the high *SPINT1-AS1* expression was significantly related to the characters, including age (\>65 years old vs ≤65 years old: 59.0% vs 31.7%, *P*=0.007) and tumor size (≤4 cm vs \>4 cm: 74.3% vs 51.7%, *P*=0.024). However, there was no significant difference between *SPINT1-AS1* expression and clinicopathological factors, including gender (*P*=0.089), family history (*P*=0.613), drinking history (*P*=0.216), smoking history (*P*=0.259), differentiation (*P*=0.477), T classification (*P*=0.723), N classification (*P*=0.832), and location (*P*=0.117). *SPINT1 mRNA* expression was upregulated in 58.3% (21/36) ESCC tissues in \>65 years old group, while this percentage was significantly lower in ≤65 years old group of 33.3% (21/63) (*P*=0.007). The same tendency was also observed in male patients (male vs female: 66.7% vs 46.0%, *P*=0.048). There was no significant correlation between *SPINT1 mRNA* and clinicopathological factors including family history (*P*=0.636), drinking history (*P*=0.219), smoking history (*P*=0.472), differentiation (*P*=0.444), T classification (*P*=0.796), N classification (*P*=0.704), tumor size (*P*=0.613), and location (*P*=0.323).Table 3Clinicopathological characteristics and SPINTI-ASI and SPINTI mRNA expression level of 99 ESCC casesVariablesN*SPINTI-ASI *expression*P* value*SPINTI mRNA* expression*P* valueHigh (n=39)Low (n=60)High (n=36)Low (n=63)Age (years) ≤655716410.007^a^15420.015^a^ \>654223192121Gender Female4614320.08912340.048^a^ Male5325282429Family history Positive3613230.61312240.636 Negative6326372439Drinking history (years) ≤106824440.21622460.219 \>103115161417Smoking history (years) ≤106523420.25922430.472 \>103416181420Differentiation Well13760.477670.444 Moderate5421332133 Poor321121923T classification T1--T22611150.72310160.796 T37328452647N classification N05221310.83218340.704 N1+ N2+ N34718291829Tumor size (cm) ≤46029310.024 ^a^23370.613 \>43910291326Location Upper17890.117890.323 Middle6722452146 Low159678[^3][^4]

The diagnostic value of SPINT1-AS1 and SPINT1 mRNA expression in ESCC {#S0003-S2004}
---------------------------------------------------------------------

The ROC curve analysis illustrated that the expression level of *SPINT1-AS1* and *SPINT1 mRNA* was able to distinguish ESCC tissues from normal tissues, with AUC value of 0.638 (*P*=0.001, 95% CI: 0.560--0.716, [Figure 2](#F0002){ref-type="fig"}) and 0.625 (*P*=0.002, 95% CI, 0.547--0.703, [Figure 2](#F0002){ref-type="fig"}), respectively.Figure 2The ROC curve analysis of *SPINT1-AS1* and *SPINT1 mRNA*. The expression level of *SPINT1-AS1* and *SPINT1 mRNA* was able to distinguish ESCC tissues from normal tissues, with AUC value of 0.638 (*P*=0.001) and 0.625 (*P*=0.002).**Abbreviations:** ROC, receiver operating characteristic; AUC, the area under the ROC curve; ESCC, esophageal squamous cell carcinoma; *SPINT1-AS1*, serine peptidase inhibitor, Kunitz type 1 antisense RNA1; *SPINT1*, serine peptidase inhibitor, Kunitz type 1.

The prognostic values of SPINT1-AS1 and SPINT1 mRNA expression in ESCC {#S0003-S2005}
----------------------------------------------------------------------

To assess the potential role of *SPINT1-AS1* and *SPINT1 mRNA* expression on the prognosis of ESCC, the Kaplan--Meier survival analysis and log-rank tests for OS were conducted on 99 patients who had intact follow-up information. The median survival time for the high *SPINT1-AS1*expression group was 40 months, while it was 35 months for the low *SPINT1-AS1* expression group. As it is shown in [Figure 3A](#F0003){ref-type="fig"}, the OS is shorter in *SPINT1-AS1* low-expressed patients than those of high levels of SPINT1-AS1 (*P*=0.044, HR=0.631, 95% CI: 0.403--0.989). The 5-year OS rate for the high *SPINT1 mRNA* expression group was 11.1%, while it was 6% in the compared groups. The results revealed that *SPINT1 mRNA* expression level was associated with the OS time (*P*=0.001, HR =0.466; 95% CI, 0.296--0.733, [Figure 3B](#F0003){ref-type="fig"}).Figure 3Kaplan-Meier survival curves for 99 ESCC based on *SPINT1-AS1* and *SPINT1 mRNA* expression level. The *x*-axis represents survival time after surgery, and the *y*-axis represents cumulative OS. (**A**) Patients with low *SPINT1-AS1* expression had a significantly poorer prognosis (shorter five-year survival rate) than those with high *SPINT1-AS1* expression (imaginary line) (*P*=0.044). (**B)**. Patients with low *SPINT1 mRNA* expression had a significantly poorer prognosis (shorter five-year survival rate) than those with high *SPINT1 mRNA* expression (imaginary line) (*P*=0.001).**Abbreviations:** ESCC, esophageal squamous cell carcinoma; *SPINT1-AS1*, serine peptidase inhibitor, Kunitz type 1 antisense RNA1; *SPINT1*, serine peptidase inhibitor, Kunitz type 1; OS, overall survival.

SPINT1-AS1 expression and the indicator for survival {#S0003-S2006}
----------------------------------------------------

The association between *SPINT1-AS1* expression and prognosis of ESCC patients was evaluated by univariate analysis and multivariate analysis. As shown in [Table 4](#T0004){ref-type="table"}, the OS of those patients was significantly dependent on family history (*P*=0.022, HR=0.596, 95% CI, 0.382--0.929), differentiation (*P*=0.009), N classification (*P*=0.000, HR=0.279, 95% CI, 0.169--0.461), and *SPINT1-AS1* expression levels (*P*=0.006, HR=0.525, 95% CI, 0.331--0.833). Thus, these factors were enrolled in the multivariate Cox regression analysis. The expression of *SPINT1-AS1* (*P*=0.030, HR=0.598, 95% CI: 0.376--0.953) was an independent indicator for the OS in ESCC, along with family history (*P*=0.001, HR=2.278, 95% CI, 1.420--3.654) and N classification (*P*=0.000, HR=0.279, 95% CI: 0.169--0.461) ([Table 4](#T0004){ref-type="table"}).Table 4Univariate and multivariate cox regression analysis of overall survival in 99 ESCC casesVariablesNUnivariate analysisMultivariate analysisHR(95%CI)*P* valueHR(95%CI)*P* valueAge (years) ≤655710.335-- \>65420.801(0.510--1.257)Gender Female4610.559-- Male530.878(0.567--1.359)Family history0.001^a^ Positive3610.022^a^1 Negative630.596(0.382--0.929)2.278(1.420--3.654)Drinking history (years) ≤106810.466-- \>10311.188(0.748--1.886)Smoking history (years) ≤106510.513-- \>10341.164(0.739--1.832)Differentiation0.242 Well1310.009^a^1 Moderate540.343(0.161--0.728)0.005^a^0.552(0.252--1.209)0.137 Poor320.582(0.363--0.933)0.025^a^0.716(0.440--1.164)0.178T classification T1--T22610.247-- T3731.354(0.811--2.263)N classification0.000^a^ N05210.000^a^1 N1+ N2+ N3473.556(2.237--5.653)0.279(0.169--0.461)Tumor size (cm) ≤46010.676-- \>4391.098(0.708--1.705)Location Upper1710.534-- Middle671.071(0.510--2.250)0.856 Low150.800(0.443--1.442)0.457*SPINT1-AS1* expression0.030^a^ High3910.006^a^1 Low600.525(0.331--0.833)0.598(0.376--0.953)[^5][^6]

Discussion {#S0004}
==========

ESCC is an aggressive tumor with rapid growth rate and high opportunity of regional and distant metastasis, which contributes to the poor prognosis.[@CIT0017] Therefore, it is urgent to find an effective early biomarker for ESCC so that the tumor can be treated at the early stage. In recent years, a new insight into the pathogenesis of human tumors has emerged with the discovery of lncRNAs. To date, thousands of lncRNAs have been reported to play important roles in ESCC tumorigenesis, progression, and metastasis.[@CIT0009],[@CIT0018]--[@CIT0020] For example, *LncRNA-NEF* inhibits proliferation, migration, and invasion of ESCC through inactivating wnt/β-catenin pathway.[@CIT0009] *HOTAIR* directly downregulates the expression of *WIF-1* and activates the Wnt/β-catenin signaling pathway to promote the migration and invasion of ESCC.[@CIT0014] *LncRNACASC9* promotes ESCC metastasis through upregulating *LAMC2* expression by interacting with the CREB-binding protein.[@CIT0019] Upregulation of the long noncoding RNA *PCAT-1* correlates with advanced clinical stage and poor prognosis in ESCC.[@CIT0020] Although the function of these dysregulated lncRNAs in ESCC has previously been reported, the function of *SPINT1-AS1* in ESCC has not been reported. In this study, we performed qRT-PCR analysis of *SPINT1-AS1* and *SPINT1 mRNA* to investigate its clinical value on the prognosis of ESCC.

*SPINT1-AS1* is transcribed from the reverse strand of the *SPINT1* locus, located at 15q15.1, and consists of three exons. The sense transcript *SPINT1 mRNA* is transcribed from the forward strand of the same locus and consists of 10 exons. Both play important roles in a number of human malignant tumors development and progression, including cell proliferation, migration, invasion, and metastasis. In this study, we revealed that *SPINT1-AS1* and *SPINT1 mRNA* were downregulated in ESCC compared with matched normal tissues. Also, the *SPINT1-AS1* expression level was positively associated with the expression of *SPINT1 mRNA* in ESCC tissues. Moreover, low *SPINT1-AS1* expression was significantly correlated with age, tumor size, and short OS. S*PINT1 mRNA* expression was related to the age, gender, and OS. Hence, *SPINT1-AS1* and *SPINT1 mRNA* might be a potential biomarker for therapeutic evaluation of ESCC.

*SPINT1*, also known as HGF activator (*HGFA*) inhibitor type 1 (*HAI-1*), is a Kunitz-type serine protease inhibitor which expresses on the surface of most epithelial cells.[@CIT0011],[@CIT0021],[@CIT0022] This protease is reported to be increased or decreased in cancer tissue and contribute to cancer progression.[@CIT0023] In prostate cancer, breast cancer, pancreatic ductal adenocarcinoma, colorectal cancer, and thyroid cancer, it has been reported that the high expression of *HAI-1* is possibly involved in the progression of these cancers.[@CIT0016],[@CIT0024]--[@CIT0027] However, *HAI-1* showed a remarkable decrease in gastric cancer and endometrial cancer.[@CIT0014],[@CIT0015] These seemingly contradictory observations highlighted that the role of *SPINT1* may be organ-specific. In our study, the expression of *SPINT1-AS1* and *SPINT1 mRNA* was observed to be significantly downregulated in ESCC tissues than in matched normal tissues. From the survival analysis, we observed that patients with low levels of *SPINT1-AS1* and *SPINT1 mRNA* expression had significantly shorter OS than those with high levels of *SPINT1-AS1* and *SPINT1 mRNA* expression. The lower *SPINT1* expression might cause deregulated pericellular activities of proteases and promoted the proteolytic degradation of the basement membrane and extracellular matrix, resulting in a more invasive phenotype. Therefore, decreased expression of *SPINT1-AS1* and *SPINT1 mRNA* might be unfavorable prognostic indicators in ESCC. Whether the *SPINT1* expression is critical to ESCC development or progression needs to be further investigated.

We reported that the mRNA level of *SPINT1* is decreased significantly in ESCC tissues. A decrease in *SPINT1 mRNA* expression would allow for a more potent influence from lncRNA, because a lower level of *SPINT1* would be processed. Our results revealed that *SPINT1-AS1* and *SPINT1 mRNA* expression were significantly higher in long OS compared with the poor OS, suggesting that *SPINT1-AS1* may have other functions independent of its mRNA accelerative activity. It does regulate *SPINT1* activity but also plays roles in tissue injury and a possible role at the invasion front in cancer.

However, certain limitations in our study should be addressed as follows. A limitation of this study is that we did not measure the serum levels of *SPINT1* in our patients. A limited number of patients (99 cases) might result in bias in the final results. Besides, the molecular mechanisms underlying the altered expression of *SPINT1-AS1* in ESCC cell lines and mouse model need to be further addressed.

Conclusions {#S0005}
===========

In conclusion, we found that the expression of *SPINT1-AS1* lncRNA and *SPINT1 mRNA* was downregulated in ESCC tissues which could contribute to tumor progression. This, in turn, impacts patients' postoperative survival time and can serve as an auxiliary index for predicting the prognosis of ESCC patients. It was suggested that both lncRNA and mRNA may be therapeutic targets and prognosis markers for ESCC.
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